Strategist PLGA Nano-capsules to Deliver siRNA for Inhibition of Carcinoma and Neuroblastoma Cell Lines by Knockdown of MYC Proto-oncogene using CPPs and PNA

Raichur, Archana; Nakajima, Yoshio; Nagaoka, Yutaka; Matsumoto, Kotaro; Mizuki, Toru; Kato, Kazunori; Maekawa, Toru; Kumar, D. Sakthi

doi:10.17756/nwj.2015-005

Cited by 4 publications

(2 citation statements)

References 51 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polylactic-co-glycolic acid (PLGA) nanoparticles has been approved as a drug delivery system in humans by the Food and Drug Administration (FDA) due to its biocompatibility and biodegradability [ 24 ] and has demonstrated the potential to deliver nucleic acids in biological systems [ 25 ]. Due to its abilities in endosomal escape and sustained release, it has been widely used in siRNA-mediated gene silencing applications [ 26 , 27 ]. Hence, using such nanoparticles as siRNA carriers would mitigate the rapid degradation and poor intracellular internalization effects of siRNA.…”

Section: Introductionmentioning

confidence: 99%

Study of siRNA Delivery via Polymeric Nanoparticles in Combination with Angiogenesis Inhibitor for The Treatment of AFP-Related Liver Cancer

Punuch

Wongwan

Jantana

et al. 2022

IJMS

View full text Add to dashboard Cite

Angiogenesis inhibitor drugs have been explored as important pharmacological agents for cancer therapy, including hepatocellular carcinoma. These agents have several drawbacks, such as drug resistance, nonspecific toxicity, and systemic side effects. Therefore, combination therapy of the drug and small interfering RNA could be a promising option to achieve high therapeutic efficacy while allowing a lower systemic dose. Therefore, we studied adding an alpha-fetoprotein siRNA (AFP-siRNA) incorporated on polymeric nanoparticles (NPs) along with angiogenesis inhibitor drugs. The AFP siRNA-loaded NPs were successfully synthesized at an average size of 242.00 ± 2.54 nm. Combination treatment of AFP-siRNA NPs and a low dose of sunitinib produced a synergistic effect in decreasing cell viability in an in vitro hepatocellular carcinoma (HCC) model. AFP-siRNA NPs together with sorafenib or sunitinib greatly inhibited cell proliferation, showing only 39.29 ± 2.72 and 44.04 ± 3.05% cell viability, respectively. Moreover, quantitative reverse transcription PCR (qRT-PCR) demonstrated that AFP-siRNA incorporated with NPs could significantly silence AFP-mRNA expression compared to unloaded NPs. Interestingly, the expression level of AFP-mRNA was further decreased to 28.53 ± 5.10% when sunitinib was added. Therefore, this finding was considered a new promising candidate for HCC treatment in reducing cell proliferation and enhancing therapeutic outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Study of siRNA Delivery via Polymeric Nanoparticles in Combination with Angiogenesis Inhibitor for The Treatment of AFP-Related Liver Cancer

Punuch

Wongwan

Jantana

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Folate-targeted, pegylated chitosan nanoparticles were used to encapsulate anti- c-myc siRNA associated with packaging RNA, to give a dual-targeting anti-tumor system that improved cellular uptake, gene silencing, and cancer cell death [ 67 ]. As a further example, Raichur et al [ 68 ] used a layer-by-layer approach to associate anti- c-myc siRNA with poly(lactic-co-glycolic acid) hollow nanoparticles. In vitro experiments showed that the nanoparticles were taken up by aggressive cancer cells and reduced c-myc expression with loss of cell viability.…”

Section: Anti- C-myc -Sirnamentioning

confidence: 99%

Anti-c-myc RNAi-Based Onconanotherapeutics

2020

View full text Add to dashboard Cite

Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly applicable and more effective form of cancer treatment than is currently available. The endogenous mechanism of RNA interference (RNAi), through which small RNA molecules induce gene silencing by binding to complementary mRNA transcripts, represents an attractive avenue for c-myc inhibition. However, the development of a clinically viable, anti-c-myc RNAi-based platform is largely dependent upon the design of an appropriate carrier of the effector nucleic acids. To date, organic and inorganic nanoparticles were assessed both in vitro and in vivo, as carriers of small interfering RNA (siRNA), DICER-substrate siRNA (DsiRNA), and short hairpin RNA (shRNA) expression plasmids, directed against the c-myc oncogene. We review here the various anti-c-myc RNAi-based nanosystems that have come to the fore, especially between 2005 and 2020.

show abstract

Lomefloxacin-loaded PLGA hollow nanospheres for healing MRSA-infected diabetic wound; optimization, in vitro and in vivo studies

Gebreel,

Abdellatif,

Attia

2024

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Strategist PLGA Nano-capsules to Deliver siRNA for Inhibition of Carcinoma and Neuroblastoma Cell Lines by Knockdown of MYC Proto-oncogene using CPPs and PNA

Cited by 4 publications

References 51 publications

Study of siRNA Delivery via Polymeric Nanoparticles in Combination with Angiogenesis Inhibitor for The Treatment of AFP-Related Liver Cancer

Study of siRNA Delivery via Polymeric Nanoparticles in Combination with Angiogenesis Inhibitor for The Treatment of AFP-Related Liver Cancer

Anti-c-myc RNAi-Based Onconanotherapeutics

Lomefloxacin-loaded PLGA hollow nanospheres for healing MRSA-infected diabetic wound; optimization, in vitro and in vivo studies

Contact Info

Product

Resources

About